Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia

Tam, C.S. orcid.org/0000-0002-9759-5017, Opat, S., D'Sa, S. et al. (33 more authors) (2024) Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia. Blood Advances, 8 (7). pp. 1639-1650. ISSN 2473-9529

Abstract

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution: https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode All other rights reserved.

Keywords: Humans; Waldenstrom Macroglobulinemia; Myeloid Differentiation Factor 88; Biomarkers; Adenine; Piperidines; Pyrazoles; Pyrimidines
Dates:
  • Published: 9 April 2024
  • Published (online): 28 March 2024
  • Accepted: 14 January 2024
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Clinical Dentistry (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 11 Jun 2024 15:01
Last Modified: 11 Jun 2024 15:01
Published Version: http://dx.doi.org/10.1182/bloodadvances.2023010906
Status: Published
Publisher: American Society of Hematology
Refereed: Yes
Identification Number: 10.1182/bloodadvances.2023010906
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics